Firefly luciferase mRNA-LNP

Name: Firefly luciferase mRNA-LNP
Brand: MedChemExpress
SKU: HY-153229
Rating: 4.5 (1 reviews)

Cat. No.: HY-153229: Data Sheet
SDS

COA
Handling Instructions
FAQs
Technical Support

Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) containing firefly luciferase mRNA. Firefly luciferase mRNA-LNP exhibits a stable nanostructure, in which LNP plays a key role in effectively protecting and transporting mRNA to cells. Luciferase is a bioluminescent reporter gene for gene regulation and functional studies. Firefly Luciferase mRNA-LNP expresses firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Firefly luciferase mRNA-LNP is studied in research for RNA delivery, cell viability, and translation efficiency.

For research use only. We do not sell to patients.

Firefly luciferase mRNA-LNP Chemical Structure

Size	Stock	Quantity
Solvent
100 μg (135.199 μg/mL * 0.74mL in buffer)	In-stock	Estimated Time of Arrival: December 31
Solvent
500 μg (135.199 μg/mL * 3.7mL in buffer)	In-stock	Estimated Time of Arrival: December 31

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Firefly luciferase mRNA-LNP (5-20 ng, 24 h) significantly increases the transfection efficiency dose-dependently in HepG2 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Firefly luciferase mRNA-LNP (2 μg, i.v., single dose) allows total luminescent flux in C57BL/6 mice^[3].
Firefly luciferase mRNA-LNP (1 μg, i.m., on day 1 and day 21) is formulated with either ALC-0315 or SM-102, and SM-102 has 60% higher expression level of luciferase protein than ALC-0315 and cKK-E12 in BALB/c mice^[4].
Firefly luciferase mRNA-LNP (5-20 μg, i.m., single dose) induces activation of Aif1 in the hypothalamus but not in the prefrontal cortex of adult Balb/c male mice^[5].
Firefly luciferase mRNA-LNP (5 μg, i.m./i.v./i.p./i.t., single dose) results in a large portion of the luciferase activity as well as high levels of protein production in the liver, and significant bioluminescent signal in lungs and muscles of BALB/c mouse model^[6].
Firefly luciferase mRNA-LNP (5 μg, i.d./s.c., single dose) results in protein production only at the site of injection in BALB/c mouse model^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice aged 6 weeks^[1]
Dosage:	0.1, 1.0, 5.0 μg
Administration:	Intradermal injection (i.d.)/Intraperitoneal injection (i.p.)/Subcutaneous injection (s.c.)/Intramuscular injection (i.m.)/Intravenous injection (i.v.)/Intratracheal injection (i.t.)
Result:	Could not measure signal when mice were injected with 0.1 μg of mRNA-LNPs. Resulted in the highest amount of peak protein production and the shortest duration of expression with intravenous delivery. Did not result in measurable luciferase expression in the liver or other anatomical sites with subcutaneous delivery. Resulted in the longest duration of translation with intramuscular and intradermal delivery. Allowed saturation of the uptake or translational capacity of the intradermal space with intradermal delivery. Observed linear dose response with intravenous injection. Led to similar levels of peak translation at 4 h post injection with all three doses, but the increased doses extended the duration of translation from 5 (1.0 μg) to 10 (5.0 μg) days.

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Firefly luciferase mRNA-LNP]

Shipping

Shipping with dry ice.

Storage

-80°C

Purity & Documentation

Select Batch:

Data Sheet (269 KB) SDS (251 KB)

COA (240 KB)

Handling Instructions (2659 KB)

References

[1]. Tenchov, R., et al., (2021). Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS nano, 15(11), 16982-17015. [Content Brief]

[2]. Xu YZ, et al. Promoter deletion analysis using a dual-luciferase reporter system. Methods Mol Biol. 2013;977:79-93. [Content Brief]

[3]. El-Mayta, R., et al., (2023). Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing. Journal of visualized experiments: JoVE, (191), 10.3791/64810. [Content Brief]

[4]. Zhang, L., et al., (2023). Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ vaccines, 8(1), 156. [Content Brief]

[5]. Kirshina, A. S., et al. (2022), "Effects of various mRNA-LNP vaccine doses on neuroinflammation in BALB/c mice", Bulletin of RSMU, no. 6, p. 119–125.

[6]. Pardi, N., et al., (2015). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of controlled release: official journal of the Controlled Release Society, 217, 345–351. [Content Brief]